Entera Bio

Entera Bio Inventory/Revenue

The Inventory to Revenue Ratio of Entera Bio (ENTX) as of Nov 22, 2026 is -219.40 %. In the previous year, Inventory to Revenue Ratio was -25.48 % — a change of 761.10% (lower).

Inventory/Revenue

-219.40 %

YoY

761.10%

Last updated:

Inventory to Revenue Ratio of Entera Bio is 2022 -219.40 % . Inventory to Revenue Ratio of Entera Bio was 2021 -25.48 % . It decreases by 761.10% lower compared to the previous year.

The Entera Bio Inventory/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory/Revenue
Date
Inventory/Revenue
Jan 1, 2018
26.00 USD
Jan 1, 2019
32.20 USD
Jan 1, 2020
-25.48 USD
Jan 1, 2022
-219.40 USD
The Entera Bio Inventory/Revenue history
YEARInventory/RevenueYoY
-219.40 %+761.10%
-25.48 %-179.12%
32.20 %+23.86%
26.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entera Bio stock

Inventory to Revenue Ratio of Entera Bio is -219.40 % in 2022.

Inventory to Revenue Ratio of Entera Bio changed from -25.48 % to -219.40 %, representing a 761.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Inventory to Revenue Ratio Entera Bio since 2006 – with annual values, charts, and detailed analysis.

The Inventory/Revenue ratio shows what percentage of revenue is held as inventory. Rising ratios may indicate slowing demand or inventory management issues.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Inventory to Revenue Ratio's Entera Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Inventory to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Inventory to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Entera Bio

All Key Metrics — Entera Bio